IL1B and early-onset autosomal dominant Alzheimer disease: UB-SCG-51 administration has been shown to lower the expression of pro-inflammatory cytokines, namely Il-1β, CCL3, CCL12, and Trem2, which are mediators of glial activation and contribute to Alzheimer’s disease progression.